Teva Pharmaceuticals and mAbxience Join Hands to Develop Biosimilar Candidates for Treating Oncology Indications

Shots: Teva Pharmaceuticals and mAbxience have signed a strategic licensing agreement across various markets incl. the EU and the US to develop a biosimilar product that is under development as a treatment for various oncology indications As per the agreement, mAbxience will develop and produce the candidates by utilizing the knowledge of biosimilar development &…

ByDipanshu DixitApril 4, 2024

INSIGHTS+

Know Your Investor (March Edition): Qiming Venture Partners

Shots: In this reprise, we feature Qiming Venture Partners again, based on the investments in 2023. With more than 600 investments to date, Qiming boasts a strong portfolio of companies involved in Technology & Consumer and Healthcare In 2023, Qiming closed 38 funding rounds comprising 11 in the first quarter, 10 in the second, 11…

BySenior EditorMarch 26, 2024

INSIGHTS+

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Shots: The EMA approved 5 BLA and 8 New Chemical Entities in February 2024, leading to treatments for patients and advances in the healthcare industry In February 2024, the major highlighted drugs were Reblozyl to treat Transfusion-Dependent Anemia and Velsipity for the treatment of Severely Active Ulcerative Colitis PharmaShots has compiled a list of a total…

BySenior EditorMarch 20, 2024

NEWS

Fresenius Kabi Reports the US FDA’s Approval for Tyenne (Biosimilar, tocilizumab-aazg) as a Treatment of Immunological and Oncological Indications

Shots: The US FDA approved Fresenius’ Tyenne (tocilizumab-aazg) developed as a biosimilar version of Actemra (tocilizumab) According to the patent settlement agreement signed between Fresenius Kabi and Genentech for Tyenne, Fresenius has the license to market its tocilizumab products across the US as per the undisclosed licensing dates Tyenne functions as an Interleukin-6 (IL-6) receptor…

ByDipanshu DixitMarch 7, 2024

INSIGHTS+

A Complete Account of EMA Approvals in 2023

Shots: In 2023, EMA approved around 45 drugs in various therapy areas, ranging from cardiology, oncology, hematology, neurology, and dermatology to infectious diseases, genetics, pulmonary, otolaryngology, gastroenterology, ophthalmology, and endocrinology PharmaShots, in an illuminating report, brings a condensed analysis of the approved drugs with the most explored areas being Oncology, Hematology, Neurology, & Dermatology For…

BySenior EditorMarch 5, 2024

INSIGHTS+

A Complete Account of FDA Approvals in 2023

Shots: 2023 remained a year of notable approvals by the US FDA. Around 55 drugs were approved, by the US FDA in 2023 PharmaShots, in an enlightening report, brings a summarized analysis of the approved drugs. The most explored section remains Oncology, Neurology, and Hematology  For the complete report with analysis, reach out to us…

BySenior EditorFebruary 1, 2024

INSIGHTS+

Know Your Investor (January Edition): RA Capital Management LLC  

Shots:  New Year, New Us! Our hand-curated “Know Your Investor” reports will now be exploring leading investors of 2023  Founded in 2002, RA Capital forged ahead to become a key investor in life science and healthcare companies. In 2023, RA Capital closed 40 major investments in biopharma companies, devices, manufacturing, service offering firms, and diagnostics  …

BySenior EditorJanuary 31, 2024

EVENTS

e-Brain OncoVision: Connecting the Dots in Cancer Care

Gear up for the most awaited metaverse-based global event! Don’t miss out on this enlightening conference focussed on Oncology domains by Ingenious E-Brain. The virtual event “e-Brain OncoVision: Connecting the Dots in Cancer Care” is scheduled for February 15th (9:00AM EST) to February 16th, 2024 (5:30PM EST) Featuring renowned speakers from leading biopharma companies & organizations, the…

BySaurabh ChaubeyJanuary 18, 2024

INSIGHTS+

Insights+: The US FDA New Drug Approvals in August 2023

Shots: The US FDA approved 10 NDAs and 3 BLA in August 2023, leading to treatments for patients and advances in the healthcare industry. The CDER and CBER approved 89 novel products in 2023 In August 2023, the major highlights drugs were Zurzuvae (zuranolone) approval for women with postpartum depression and Veopoz (pozelimab-bbfg) for children…

BySenior EditorSeptember 20, 2023

TOP 20

Top 20 Oncology Companies Based on 2022 By Total Revenue

Shots: With more than 50% of ongoing clinical trials worldwide in oncology domains, cancer remains one of the leading causes of death worldwide. Oncology companies are steadfastly looking for innovative therapies to cure both hematologic and solid tumor cancer The global oncology drug market size in 2022 was valued at $185B and is forecasted to…

ByPrince GiriSeptember 13, 2023

Teva Pharmaceuticals and mAbxience Join Hands to Develop Biosimilar Candidates for Treating Oncology Indications

Know Your Investor (March Edition): Qiming Venture Partners

Insights+: EMA Marketing Authorization of New Drugs in February 2024

Fresenius Kabi Reports the US FDA’s Approval for Tyenne (Biosimilar, tocilizumab-aazg) as a Treatment of Immunological and Oncological Indications

A Complete Account of EMA Approvals in 2023

A Complete Account of FDA Approvals in 2023

Know Your Investor (January Edition): RA Capital Management LLC

e-Brain OncoVision: Connecting the Dots in Cancer Care

Top 20 Oncology Companies Based on 2022 By Total Revenue

Contact US

FOLLOW US